Product Liability “FDA Defense” Prospects Hampered By Vioxx Shrapnel
This article was originally published in The Tan Sheet
Executive Summary
An "FDA defense" from product liability punitive damages will be a tough sell on Capitol Hill in the next session, in light of burgeoning concerns about FDA's handling of Vioxx and agency oversight of approvals and postmarketing